Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings 3-Year Revenue Growth Rate?

Clarus Therapeutics Holdings's Revenue per Share for the three months ended in Jun. 2022 was $0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Clarus Therapeutics Holdings's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarus Therapeutics Holdings's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's 3-Year Revenue Growth Rate falls into.

Clarus Therapeutics Holdings 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Clarus Therapeutics Holdings (OTCPK:CRXTQ) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Clarus Therapeutics Holdings 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Executives

Thomas Mcnerney & Partners Lp	10 percent owner	45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr	director	C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory	director	C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley	director, officer: Chief Executive Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson	officer: Chief Financial Officer	1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger	officer: Chief Commercial Officer	CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne	officer: Chief Administrative Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd	10 percent owner	DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402